AEROSOL THERAPY IN PATIENTS WITH CYSTIC-FIBROSIS

Citation
Mh. Schoni et Wh. Nikolaizik, AEROSOL THERAPY IN PATIENTS WITH CYSTIC-FIBROSIS, Schweizerische medizinische Wochenschrift, 127(5), 1997, pp. 158-164
Citations number
53
Categorie Soggetti
Medicine, General & Internal
ISSN journal
00367672
Volume
127
Issue
5
Year of publication
1997
Pages
158 - 164
Database
ISI
SICI code
0036-7672(1997)127:5<158:ATIPWC>2.0.ZU;2-0
Abstract
Aerosol therapy is one of the mainstays of treatment, together with re gular physiotherapy, in patients with cystic fibrosis. Inhalation can contribute to hydration of the epithelial lining fluid as well as deli vering different drugs directly to lungs. Topically administered antib iotics can protect the lungs from Pseudomonas infection, recombinant D Nase, amiloride and beta-agonists can have a positive effect on the mu cociliary clearance, and steroid inhalations can reduce inflammation. Therefore, all these drugs are part of a comprehensive treatment strat egy contributing to improvement in lung function and quality of life. Gene therapy and pharmacological correction of the chloride channel de fect are perspectives for the future. Aerosol therapy, however, is som ewhat cumbersome and requires strict patient education.